Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease 2021-2025: Market Analysis by Syndrome, Plex, Place, and Country with COVID-19 Impact & Forecast, Executive Guides, and Customization" report has been added to ResearchAndMarkets.com's offering.
COVID-19 Drives a Surge in Demand, But What is the Long Term Impact? The Microbiology Lab May Disappear While Multiplex Takes Center Stage
The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe.
Find out what the numbers are in this informative report, and find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.
Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report.
A range of dynamic trends are pushing market growth and company valuations.
Trends like:
-
Multiplex testing;
-
Pathogen evolution and pandemics;
-
Biotechnology advances in genetics;
-
Climate change;
-
Globalization;
-
The rise of rapid testing.
Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.
The report has hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available.
Key Topics Covered:
1 Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19
2 Guide for Executives, Marketing, Sales and Business Development Staff
3 Guide for Management Consultants and Investment Advisors
4 Introduction and Market Definition
4.1 What is Molecular Diagnostics
4.2 The Diagnostics Revolution
4.3 Market Definition
4.3.1 Revenues
4.4 Methodology
4.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
4.5.1 U.S. Medicare Expenditures for Clinical Testing
5 The Infectious Diseases - Market Analysis by Disease
5.1 HIV - Human Immunodeficiency Virus (AIDS)
5.1.1 Virology
5.1.1.1 Classification
5.1.1.2 Structure and genome
5.1.1.3 Tropism
5.1.1.4 Replication cycle
5.1.1.5 Genetic variability
5.1.2 Diagnosis
5.1.3 Testing
5.1.3.1 Antibody tests
5.1.3.2 Point of Care Tests (POCT)
5.1.3.3 Antigen Tests
5.1.3.4 Nucleic acid-based tests (NAT)
5.1.3.5 Other tests used in HIV treatment
5.1.4 Market Opportunity Analysis
5.2 HBV - Hepatitis B
5.2.1 Virology
5.2.1.1 Genome
5.2.1.2 Pathogenesis
5.2.1.3 Hepatitis B virus replication
5.2.1.4 Serotypes and genotypes
5.2.2 Mechanisms
5.2.3 Diagnosis
5.2.4 Market Opportunity Analysis
5.3 HCV - Hepatitis C
5.3.1 Taxonomy
5.3.2 Structure
5.3.2.1 Genome
5.3.3 Molecular biology
5.3.4 Replication
5.3.5 Genotypes
5.3.5.1 Clinical importance
5.3.6 Market Opportunity Analysis
5.4 HPV - Human papillomavirus
5.4.1 Virology
5.4.1.1 E6/E7 proteins
5.4.1.2 Role in cancer
5.4.1.3 E2 research
5.4.1.4 Latency period
5.4.1.5 Clearance
5.4.2 Diagnosis
5.4.2.1 Cervical testing
5.4.2.2 Oral testing
5.4.2.3 Testing men
5.4.2.4 Other testing
5.4.3 Market Opportunity Analysis
5.5 Influenza
5.5.1 Virology
5.5.1.1 Types of virus
5.5.1.2 Influenzavirus A
5.5.1.3 Influenzavirus B
5.5.1.4 Influenzavirus C
5.5.1.5 Structure, properties, and subtype nomenclature
5.5.1.6 Replication
5.5.2 Testing
5.5.2.1 Advantages/Disadvantages of Molecular Assays
5.5.3 Market Opportunity Analysis
5.6 CTGC - Chlamydia/Gonorhea
5.6.1 Gonorrhea
5.6.1.1 Diagnosis
5.6.1.2 Screening
5.6.2 Chlamydia
5.6.2.1 Diagnosis
5.6.2.2 Screening
5.6.3 Testing
5.6.3.1 Nucleic acid amplification tests (NAATs)
5.6.3.2 Performance of NAAT Tests
5.6.4 Market Opportunity Analysis
5.7 Tuberculosis
5.7.1 Mycobacteria
5.7.2 Diagnosis
5.7.2.1 Active tuberculosis
5.7.2.2 Latent tuberculosis
5.7.3 Epidemiology
5.7.4 Molecular Diagnostic Tests
5.7.5 Market Opportunity Analysis
5.8 MRSA - Methicillin-resistant Staphylococcus aureus
5.8.1 Diagnosis
5.8.2 FDA Approved Molecular Tests
5.8.3 Market Opportunity Analysis
5.9 VRE - Vancomycin-resistant Enterococcus
5.9.1 FDA Approved MDx Tests for VRE
5.9.2 Market Opportunity Analysis
5.10 Blood Screening
5.10.1 Collection and Testing
5.10.2 FDA Approved Multiplex Assays
5.10.3 Market Opportunity Analysis
5.11 COVID-19
5.11.1 Signs and symptoms
5.11.2 Transmission
5.11.3 Diagnosis
5.11.4 Prevention
5.11.5 Management
5.11.6 Prognosis
5.12 Pandemic Diagnostics
5.12.1 Risk Management - Spark and Spread
5.12.2 Dx Technology - Nucleic Acid Based
5.12.3 Dx Technology - Immunoassay & Serology
5.12.4 Time to Market and Preparedness Issues
5.12.5 Unrecognized Role of Multiplex in Pandemic Management